Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
News Releases
News Releases
The information set forth in each press release posted on this page was factually accurate on the date it was issued. While these press releases remain on the Company's website, the Company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of the press releases should not rely upon the information as current or accurate after their issuance dates.
WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 11, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Credit Suisse 28 th Annual Healthcare Conference in Scottsdale, Arizona on Tuesday, November 12 th
– Third-Quarter Revenue of $668.0 Million – – Third-Quarter GAAP Earnings per Share of $1.46 and Non-GAAP Earnings per Share of $1.69 – – Updates 2019 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 6, 2019-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 23, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 4.25% senior notes due 2028 (the “notes”) in an unregistered
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 21, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2019 financial results on Wednesday, November 6 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday,
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 21, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $500 million in aggregate principal amount of senior notes due 2028 (the “notes”) in an unregistered offering, subject to market conditions.
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 16, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 37 scientific posters, both independently and collaboratively with clients, at Neuroscience 2019, the
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 3, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that the Company has been selected by Alzheimer’s Research UK to join the Dementia Consortium . The Consortium is a global charity-industry partnership aimed at funding
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 1, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Virginia M. (Gina) Wilson , the recently retired Senior Executive Vice President and Chief Financial Officer of Teachers Insurance and Annuity
New EndoScan-V™ endotoxin detection software and Celsis ® automated detection platform for rapid sterility introduced to address unmet industry needs WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 9, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of two new
The two-day event will highlight strategies for delivering drugs to patients faster WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 5, 2019-- Charles River Laboratories International, Inc. is proud to host the 3 rd Annual World Congress : Delivering Therapies to the Clinic Faster on September 23-24, 2019
- Company to Host an Investor Day on September 12 th - WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Baird 2019 Global Healthcare Conference in New York on Thursday, September 5 th , at
– Second-Quarter Revenue of $657.6 Million – – Second-Quarter GAAP Earnings per Share of $0.88 and Non-GAAP Earnings per Share of $1.63 – – Updates 2019 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 31, 2019-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 16, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2019 financial results on Wednesday, July 31 st , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, July
WILMINGTON, Mass. & SAN FRANCISCO --(BUSINESS WIRE)--Jul. 9, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the planned opening of the Charles River Accelerator and Development Lab (CRADL™) in South San Francisco in early 2020.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 3, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5 th , at 8:30 a.m.
Access to Resero’s TurboToxicology™ will provide faster delivery of high-quality toxicology reports WILMINGTON, Mass. --(BUSINESS WIRE)--May 16, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has invested in Resero Analytics™, a software company focused on
– First-Quarter Revenue of $604.6 Million – – First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share of $1.40 – – Reaffirms 2019 Guidance Including Citoxlab – WILMINGTON, Mass. --(BUSINESS WIRE)--May 7, 2019-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 11, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2019 financial results on Tuesday, May 7 th , before the market opens. A conference call has been scheduled to discuss this information on Tuesday, May 7 th ,
Behind every patient stands thousands of scientists and researchers collaborating to develop life-saving drugs. Jenne’s story highlights the importance of that work. WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 9, 2019-- Charles River Laboratories International, Inc.
Researchers will highlight work in BRCA-deficient and rare pediatric cancers WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 26, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Raymond James 40 th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 5
– Fourth-Quarter Revenue of $601.5 Million and Full-Year Revenue of $2.27 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.21 and Non-GAAP Earnings per Share of $1.49 – – Full-Year GAAP Earnings per Share of $4.59 and Non-GAAP Earnings per Share of $6.03 – – Provides 2019 Guidance – –
– Further Strengthens Charles River’s Position as the Leading Global Early-Stage CRO – – Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.15 in 2019 and At Least $0.35 in 2020 – WILMINGTON, Mass. --(BUSINESS WIRE)--Feb. 13, 2019-- Charles River Laboratories International,
Charles River will offer access to ToxTracker ® , expanding the Company’s portfolio of genetic toxicology assays WILMINGTON, Mass. & LEIDEN, The Netherlands --(BUSINESS WIRE)--Jan. 30, 2019-- Charles River Laboratories International, Inc (NYSE: CRL) and Toxys have entered into an agreement to offer
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 17, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2018 financial results and provide 2019 guidance on Wednesday, February 13 th , before the market opens.
The 2019 Gender-Equality Index highlights 230 firms that are trailblazers in their commitment to gender diversity in the workplace WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 16, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it is pleased to have been selected
Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform WILMINGTON, Mass. & SAN FRANCISCO --(BUSINESS WIRE)--Jan. 11, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 7, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco, California , on Tuesday, January 8 th , at 10:00 a.m. PST ( 1:00 p.m.
WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 27, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore ISI HealthConX Conference in Boston on Thursday, November 29 th , at 11:00 a.m. ET . Management will present an overview of Charles
Team of oncology experts expand data in Tumor Model Compendium and present strong portfolio at industry conferences WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 13, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced new additions to the Tumor Model Compendium .
– Third-Quarter Revenue of $585.3 Million – – Third-Quarter GAAP Earnings per Share of $1.22 and Non-GAAP Earnings per Share of $1.53 – – Updates 2018 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 30, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48
New partnership allows Charles River’s clients access to Distributed Bio’s antibody discovery platforms WILMINGTON, Mass. & SAN FRANCISCO --(BUSINESS WIRE)--Oct. 25, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 16, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it was awarded a five-year, $95.7 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), which is one of the largest institutes of the
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 10, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2018 financial results on Wednesday, November 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday,
WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 30, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Wells Fargo 2018 Healthcare Conference in Boston on Wednesday, September 5 th , at 9:40 a.m.
– Second-Quarter Revenue of $585.3 Million – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $1.62 – – Increases 2018 Revenue Growth and Earnings per Share Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 8, 2018-- Charles River Laboratories International,
– Schedules Investor Day on August 14 th – WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 11, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2018 financial results on Wednesday, August 8 th , before the market opens.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2018 Global Healthcare Conference in New York, New York , on Wednesday, June 6 th , at 11:00 a.m.
– First-Quarter Revenue of $494.0 Million – – First-Quarter GAAP Earnings per Share of $1.08 and Non-GAAP Earnings per Share of $1.38 – – Updates 2018 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--May 10, 2018-- Charles River Laboratories International, Inc.
Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research WILMINGTON, Mass. --(BUSINESS WIRE)--May 3, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL ) today announced an extension of its long-standing collaboration with The
Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery WILMINGTON, Mass. --(BUSINESS WIRE)--May 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 12, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2018 financial results on Thursday, May 10 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 10 th
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 10, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts is presenting 13 scientific posters, both independently and collaboratively with clients, and will highlight an enhanced oncology
Charles River will provide clients access to PathoQuest’s NGS-based testing solutions WILMINGTON, Mass. & PARIS--(BUSINESS WIRE)--Apr. 9, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest today announced an expansion of their strategic partnership agreement to provide
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 3, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of MPI Research for approximately $800 million in cash, subject to certain customary adjustments.
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 3, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 5.5% senior notes due 2026 (the “notes”) in an unregistered
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 26, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has refinanced its existing $1.0 billion of revolving credit facility due 2021 with a new $1.55 billion revolving credit facility due 2023, and its existing $650.0
The Company is adding Devon Park , doubling its laboratory footprint in Penn. WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 8, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) recently announced several key expansions to its global Biologics Testing Solutions infrastructure to support
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 39 th Annual Institutional Investors Conference in Orlando, Florida , on Tuesday, March 6 th , at 3:25 p.m.
The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies WILMINGTON, Mass. --(BUSINESS WIRE)--Feb. 21, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) recently announced the launch of its new online Tumor Model
– Dr. Davide Molho Appointed to President and Chief Operating Officer – – Birgit Girshick Appointed to Corporate Executive Vice President, Discovery and Safety Assessment – WILMINGTON, Mass. --(BUSINESS WIRE)--Feb. 13, 2018-- Charles River Laboratories International, Inc.
– Fourth-Quarter Revenue of $478.5 Million and Full-Year 2017 Revenue of $1.86 Billion – – Fourth-Quarter GAAP Loss per Share of $0.63 and Non-GAAP Earnings per Share of $1.40 – – Full-Year GAAP Earnings per Share of $2.54 and Non-GAAP Earnings per Share of $5.27 – – Provides 2018 Guidance – –
– Enhances Charles River’s Position as a Leading Global Early-Stage CRO – – Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.25 in 2018 and Approximately $0.60 in 2019 – WILMINGTON, Mass. --(BUSINESS WIRE)--Feb. 13, 2018-- Charles River Laboratories International, Inc.
Signs collaboration agreement with AstraZeneca to offer state-of-the-art technology to clients WILMINGTON, Mass. --(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 25, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2017 financial results and provide 2018 guidance on Tuesday, February 13 th , before the market opens.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 16, 2018-- Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Jean-Paul Mangeolle, former President of AB SCIEX, to its Board of Directors. Mr. Mangeolle’s extensive experience leading global life science and
– Establishes Charles River as a Premier Source for Immunology Contract Research Services – WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 11, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 8, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9 th , at 11:30 a.m. PST (2:30 p.m.
WILMINGTON, Mass. --(BUSINESS WIRE)--Dec. 6, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CRISPR/Cas9 service offering with the addition of a license from ERS Genomics Limited . The license, coupled with the existing license through the
Capture Compound Mass Spectrometry technology enables target identification WILMINGTON, Mass. & LYON, France --(BUSINESS WIRE)--Nov. 28, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration.
– Third-Quarter Revenue of $464.2 Million – – Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30 – – Updates 2017 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 9, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of
WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 1, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts is presenting 27 scientific posters, both independently and collaboratively with clients, at Neuroscience 2017, the 47
Partnership with InSphero provides additional 3D solutions WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 26, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced its partnership with InSphero AG , a leading supplier of 3D solutions for in vitro drug discovery and
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 12, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) has changed the date of its third-quarter 2017 earnings release and conference call. The Company will now release financial results on Thursday, November 9 th , before the market opens.
Together, Sonia and Eric are fighting to discover a cure for genetic prion diseases WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 12, 2017-- On Tuesday, September 26, 2017 , James Foster , Chairman, President and Chief Executive Officer of Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 5, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Wells Fargo 2017 Healthcare Conference in Boston on Wednesday, September 6 th , at 9:40 a.m.
Topics include the microbiome, oncology, 3D bioprinting, and CRISPR/CAS9 gene editing WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 29, 2017-- Charles River Laboratories International, Inc. is proud to host the Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development .
Conference will engage leaders from academia and the pharmaceutical and biotechnology industries WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 15, 2017-- Breakthroughs begin here. At the Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development , leaders from across
– Second-Quarter Revenue of $469.1 Million – – Second-Quarter GAAP EPS of $1.12 and Non-GAAP EPS of $1.29 – – Updates 2017 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 9, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of
– Establishes Charles River as a Premier Source for CNS Contract Research Services – WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 7, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired Brains On-Line, a leading contract research organization (CRO)
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 13, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2017 financial results on Wednesday, August 9 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday,
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 5, 2017-- Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Dr. Martin Mackay , Executive Vice President, Alexion Pharmaceuticals Inc. , to its Board of Directors. Dr. Mackay’s extensive experience leading research
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 5, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2017 Global Healthcare Conference in New York on Wednesday, June 7 th , at 10:00 a.m. EDT .
WILMINGTON, Mass. --(BUSINESS WIRE)--May 16, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) recently announced updates to its expanding oncology discovery business, including significant additions to its online Tumor Model Compendium.
– First-Quarter Revenue of $445.8 Million – – First-Quarter GAAP EPS of $0.97 and Non-GAAP EPS of $1.29 – – Updates 2017 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--May 10, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 12, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2017 financial results on Wednesday, May 10 th before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 10 th
WILMINGTON, Mass. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 5, 2017-- Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL) today launched a multi-year strategic partnership to advance new programs spanning the disease areas of immunology, metabolic disorders and
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 3, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model.
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 13, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), today announced that it has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 6, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 38 th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 7 th , at 1:05 p.m.
– Fourth-Quarter Revenue of $466.8 Million and Full-Year 2016 Revenue of $1.68 Billion – – Fourth-Quarter GAAP Earnings per Share of $0.93 and Non-GAAP Earnings per Share of $1.21 – – Full-Year GAAP Earnings per Share of $3.22 and Non-GAAP Earnings per Share of $4.56 – – Provides 2017 Guidance – –
WILMINGTON, Mass. --(BUSINESS WIRE)--Feb. 9, 2017-- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it changed the time of its conference call to discuss fourth-quarter and full-year 2016 financial results and 2017 guidance to 8:00 a.m.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 30, 2017-- Charles River Laboratories International, Inc. (NYSE:CRL), a leading early-stage contract research organization (CRO), today announced a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 19, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2016 financial results and provide 2017 guidance on Tuesday, February 14 th , before the market opens.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 9, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 35 th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10 th , at 1:30 p.m. PST (4:30 p.m.
WILMINGTON, Mass. --(BUSINESS WIRE)--Dec. 1, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) today launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology. Through a licensing arrangement with the Broad Institute o f MIT and Harvard , Charles
WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 10, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of leading Central Nervous System (CNS) and neurological disease experts is presenting 25 scientific posters and one podium presentation, both independently
– Third-Quarter Revenue of $425.7 Million – – Third-Quarter GAAP Earnings per Share of $0.78 and Non-GAAP Earnings per Share of $1.18 – – Updates 2016 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 2, 2016-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 11, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has extended its longstanding integrated drug discovery alliance with Genentech, a member of the Roche Group . “We are proud to work with Genentech to identify
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 6, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2016 financial results on Wednesday, November 2 nd before the market opens. A conference call has been scheduled to discuss this information on Wednesday,
– Enhances Charles River’s Early-Stage Capabilities in Bioanalytical Services – WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 28, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Agilux Laboratories, Inc.
Partnership Intends to Accelerate Translation of Discoveries into Novel Therapies for Patients WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 22, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership agreement with The
WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 6, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Baird 2016 Global Healthcare Conference in New York on Wednesday, September 7 th , at 10:15 a.m.
WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 8, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium. The Milner Therapeutics Institute aims to accelerate academic
– Second-Quarter Revenue of $434.1 Million – – Second-Quarter GAAP Earnings per Share of $0.73 and Non-GAAP Earnings per Share of $1.20 – – Updates 2016 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 3, 2016-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 11, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2016 financial results on Wednesday, August 3 rd before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August
– Offers Clients an Integrated Portfolio for Biologic and Biosimilar Drug Development – WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 27, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired Blue Stream Laboratories, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 6, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York on Wednesday, June 8 th , at 10:00 a.m.
Partnership will support Moderna’s expanding pipeline and help accelerate discovery programs and development candidate progress into the clinic CAMBRIDGE, Mass. & WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 6, 2016-- Moderna Therapeutics, a clinical stage pioneer in the development of messenger RNA
– First-Quarter Revenue of $354.9 Million – – First-Quarter GAAP Earnings per Share of $0.78 and Non-GAAP Earnings per Share of $0.98 – – Updates 2016 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--May 4, 2016-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 13, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with BioMotiv, LLC , the therapeutic accelerator company associated with The Harrington Project for Discovery &
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 7, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2016 financial results on Wednesday, May 4 th before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 4 th ,
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 4, 2016-- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has completed the previously announced acquisition of WIL Research for approximately $585 million in cash, subject to certain customary adjustments.
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 7, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 37 th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 8 th , at 10:25 a.m. ET .
– Fourth-Quarter Revenue of $353.9 Million and Full-Year 2015 Revenue of $1.36 Billion – – Fourth-Quarter GAAP Earnings per Share of $0.69 and Non-GAAP Earnings per Share of $1.00 – – Full-Year GAAP Earnings per Share of $3.15 and Non-GAAP Earnings per Share of $3.76 – – Provides 2016 Guidance –
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 20, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2015 financial results and provide 2016 guidance on Wednesday, February 10th , before the market opens.
– Enhances Charles River’s Position as a Leading Global Early-Stage CRO – – Transaction Expected to be Accretive to Non-GAAP EPS by At Least $0.20 in 2016 and $0.45-$0.50 in 2017 – WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 7, 2016-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Dec. 8, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL ) today announced a significant expansion of its work with small molecule LRRK2 inhibitors, funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization
– Expands Oncology Capabilities of Charles River Discovery Services – WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 18, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Oncotest GmbH , a Freiburg, Germany -based contract research organization (CRO)
– Third-Quarter Revenue of $349.5 Million – – Third-Quarter GAAP Earnings per Share of $0.79 and Non-GAAP Earnings per Share of $1.03 – – Updates 2015 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 4, 2015-- Charles River Laboratories International, Inc.
CHICAGO --(BUSINESS WIRE)--Oct. 19, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of leading Central Nervous System (CNS) researchers is presenting 25 posters at Neuroscience 2015 , the annual meeting of the Society for Neuroscience (SfN).
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 8, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2015 financial results on Wednesday, November 4 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday,
Wellcome Trust-Funded Projects Expand Partnerships with Charles River’s Global Discovery Services Business WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 7, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL ) today announced new and continuing collaborations with three innovative drug
WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 15, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Morgan Stanley Global Healthcare Conference in New York on Thursday, September 17th , at 10:00 a.m. EDT .
– Second-Quarter Revenue of $339.6 Million – – Second-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $0.96 – – Updates 2015 Guidance for Celsis Acquisition – – Renews Strategic Partnership with AstraZeneca – – Plans to Reopen Shrewsbury, Massachusetts Facility in Early
- Leading Global CRO and Global Biopharmaceutical Company Extend Relationship to Accelerate Drug Development - WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 30, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has extended its initial three-year partnership with
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 24, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Celsis International Ltd. for $212 million in cash, subject to certain post-closing working capital
– Enhances Charles River Endotoxin and Microbial Detection’s Position as the Most Comprehensive Solution for Rapid Quality Control Testing – – Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.05 in 2015 and $0.15-$0.20 in 2016 – WILMINGTON, Mass. --(BUSINESS WIRE)--Jul.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 7, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2015 financial results on Thursday, July 30 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, July 30
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 1, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2015 Global Healthcare Conference in New York, New York on Tuesday, June 2 nd , at 10:00 a.m. EDT .
WILMINGTON, Mass. --(BUSINESS WIRE)--May 4, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at Baird’s 2015 Growth Stock Conference in Chicago, Illinois on Wednesday, May 6 th , at 9:45 a.m. CDT ( 10:45 a.m.
– First-Quarter Revenue of $320.4 Million – – First-Quarter GAAP Earnings per Share of $0.66 and Non-GAAP Earnings per Share of $0.79 – – Raises 2015 Constant-Currency Revenue Growth Guidance – – Reaffirms 2015 Reported Revenue Growth and Earnings per Share Guidance – WILMINGTON, Mass.
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 9, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2015 financial results on Wednesday, April 29 th , after the market closes. A conference call has been scheduled to discuss this information on Thursday, April
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 2, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Raymond James 36 th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March
Thomas F. Ackerman , Corporate Executive Vice President & Chief Financial Officer, Announces Planned Retirement in 2016 David R. Smith Will Transition to Chief Financial Officer Role Dr. Emily Hickey and Dr. Katherine Hilyard Promoted to New Leadership Positions in Discovery Services WILMINGTON,
WILMINGTON, Mass. --(BUSINESS WIRE)--Feb. 11, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Leerink Global Healthcare Conference in New York on Thursday, February 12 th , at 10:20 a.m. EST .
– Fourth-Quarter Revenue of $329.5 Million and Full-Year 2014 Revenue of $1.30 Billion – – Fourth-Quarter GAAP Earnings per Share of $0.59 and Non-GAAP Earnings per Share of $0.81 – – Full-Year GAAP Earnings per Share of $2.70 and Non-GAAP Earnings per Share of $3.46 – – Provides 2015 Guidance for
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 26, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2014 financial results and provide 2015 guidance on Tuesday, February 10 th , after the market closes.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 12, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the J.P. Morgan 33 rd Annual Healthcare Conference in San Francisco, California on Wednesday, January 14 th , at 9:30 a.m. PST (12:30 p.m.
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 8, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2014 financial results on Wednesday, October 29 th , after the market closes. A conference call has been scheduled to discuss this information on Thursday,
WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 8, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 9 th , at 10:00 a.m. EDT .
– Second-Quarter Revenue of $341.2 Million – – Second-Quarter GAAP Earnings per Share of $0.75 and Non-GAAP Earnings per Share of $0.97 – – Updates EPS Guidance for 2014 – – Revises Financial Reporting into Three Segments – WILMINGTON, Mass. --(BUSINESS WIRE)--Aug.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 24, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will hold a meeting for the investment community with its management team on Tuesday, August 12, 2014 in New York .
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 7, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2014 financial results on Wednesday, August 6 th , after the market closes. A conference call has been scheduled to discuss this information on Thursday, August
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 2, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2014 Global Healthcare Conference in New York, New York on Tuesday, June 3 rd , at 11:00 a.m.
WILMINGTON, Mass. --(BUSINESS WIRE)--May 5, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at Baird’s 2014 Growth Stock Conference in Chicago, Illinois on Wednesday, May 7 th , at 10:20 a.m. CDT ( 11:20 a.m. EDT ).
– First-Quarter Sales of $299.4 Million – – First-Quarter GAAP Earnings per Share of $0.67 and Non-GAAP Earnings per Share of $0.82 – – Raises Sales and Non-GAAP EPS Guidance for 2014; Reduces 2014 GAAP EPS Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Apr.
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 7, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2014 financial results on Wednesday, April 30 th , after the market closes. A conference call has been scheduled to discuss this information on Thursday, May 1
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 31, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus.
– Strengthens Position as a Full Service, Early-Stage CRO with Integrated Capabilities from Target Identification through Preclinical Development– – Transaction Expected to be Accretive to Non-GAAP EPS by $0.10 in 2014 – WILMINGTON, Mass. --(BUSINESS WIRE)--Mar.
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 3, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Cowen and Company 34 th Annual Health Care Conference in Boston, Massachusetts on Tuesday, March 4 th , at 10:00 a.m.
Fourth-Quarter Sales of $289.2 Million and Full-Year 2013 Sales of $1.17 Billion Fourth-Quarter GAAP Earnings per Share of $0.40 and Non-GAAP Earnings per Share of $0.73 Full-Year GAAP Earnings per Share of $2.15 and Non-GAAP Earnings per Share of $2.93 2014 Guidance Includes Sales Growth of 3%-5%,
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 27, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2013 financial results and provide 2014 financial guidance on Tuesday, February 11 th , after the market closes.
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 13, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the J.P. Morgan 32 nd Annual Healthcare Conference in San Francisco, California on Tuesday, January 14 th , at 10:00 a.m. PST (1:00 p.m. EST).
WILMINGTON, Mass. --(BUSINESS WIRE)--Dec. 9, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced organizational changes which are designed to continue to improve the Company’s operating efficiency across its global portfolio and enhance its ability to meet the needs of
Board of Directors Increases Stock Repurchase Authorization by an Additional $150 Million WILMINGTON, Mass. --(BUSINESS WIRE)--Dec. 3, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Craig B. Thompson , M.D., President and Chief Executive
WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 11, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Credit Suisse 2013 Healthcare Conference in Phoenix, Arizona on Wednesday, November 13 th , at 11:00 a.m. MST ( 1:00 p.m. EST ).
– Third-Quarter GAAP Sales of $292.1 Million – – Third-Quarter GAAP Earnings per Share of $0.64 and Non-GAAP Earnings per Share of $0.79 – – Updates Sales and EPS Guidance for 2013 – WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 29, 2013-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2013 financial results on Tuesday, October 29 th , after the market closes. A conference call has been scheduled to discuss this information on Wednesday,
WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2013-- Charles River Laboratories International, Inc. (NYSE:CRL) announced today the appointment of John Crowley to the role of Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer, effective September 30 .
WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 9, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10 th , at 9:10 a.m. EDT .
Second-Quarter GAAP Sales of $292.9 Million and Non-GAAP Sales of $294.4 Million Second-Quarter GAAP Earnings per Share of $0.58 and Non-GAAP Earnings per Share of $0.73 Reaffirms Sales and Non-GAAP EPS Guidance for 2013; Reduces 2013 GAAP EPS Guidance Increases Stock Repurchase Authorization by an
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 2, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2013 financial results on Wednesday, July 31 st , after the market closes. A conference call has been scheduled to discuss this information on Thursday, August
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 3, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Jefferies 2013 Global Healthcare Conference in New York, New York on Wednesday, June 5 th , at 9:30
WILMINGTON, Mass. --(BUSINESS WIRE)--May. 6, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at Baird’s 2013 Growth Stock Conference in Chicago, Illinois on Wednesday, May 8 th , at 9:45 a.m. CDT ( 10:45 a.m. EDT ).
First-Quarter Sales of $291.2 Million First-Quarter GAAP Earnings per Share of $0.53 and Non-GAAP Earnings per Share of $0.69 Updates 2013 Sales Guidance; Reaffirms 2013 EPS Guidance WILMINGTON, Mass. --(BUSINESS WIRE)--May. 1, 2013-- Charles River Laboratories International, Inc.
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 8, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2013 financial results on Wednesday, May 1 st , after the market closes. A conference call has been scheduled to discuss this information on Thursday, May 2 nd ,
WILMINGTON, Mass. --(BUSINESS WIRE)--Mar. 1, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Raymond James 34 th Annual Institutional Investors Conference in Orlando, Florida on Monday, March 4
Fourth-Quarter Sales of $280.1 Million and Full-Year 2012 Sales of $1.13 Billion Fourth-Quarter GAAP Earnings per Share of $0.47 and Non-GAAP Earnings per Share of $0.64 Full-Year GAAP Earnings per Share of $2.10 and Non-GAAP Earnings per Share of $2.74 Updates 2013 Sales Guidance; Reaffirms 2013
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 22, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2012 financial results on Wednesday, February 13 th , after the market closes. A conference call has been scheduled to discuss this information
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 7, 2013-- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has completed its acquisition of a 75% ownership of Vital River, the premier commercial provider of research models and related services in China , and a licensee of
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 7, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the J.P. Morgan 31 st Annual Healthcare Conference in San Francisco, California on Tuesday, January 8 th , at 10:00 a.m. PST (1:00 p.m. EST).
WILMINGTON, Mass. --(BUSINESS WIRE)--Dec. 12, 2012-- Charles River Laboratories International, Inc. (NYSE: CRL) today provided guidance for 2013 and reaffirmed guidance for 2012. James C. Foster , Chairman, President and Chief Executive Officer, said, “The actions we have taken in the last three
Third-Quarter Sales of $278.7 Million PCS Sales Increase 5.7% Year-Over-Year Third-Quarter GAAP Earnings per Share of $0.46 and Non-GAAP Earnings per Share of $0.65 Updates Sales and EPS Guidance for 2012 WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 30, 2012-- Charles River Laboratories International,
- Signs Agreement to Acquire Majority Ownership of Vital River - WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 30, 2012-- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has entered into an agreement to acquire 75% ownership of Vital River , the premier commercial
Leading Global CRO Partners with Global Biopharmaceutical Company to Accelerate Drug Development WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 17, 2012-- Charles River Laboratories International, Inc. (NYSE: CRL ) today announced that it has been selected by AstraZeneca (NYSE: AZN ) as its preferred
New facility provides opportunity to utilize innovative technology platforms that support drug development WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 6, 2012-- Charles River Laboratories, Inc. (NYSE: CRL) today announced the opening of its new biomedical diagnostic testing facility in Wilmington,
Expands Microbial Identification Capabilities WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 29, 2012-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Accugenix, Inc. , the premier global provider of cGMP-compliant contract microbial identification
Second-Quarter Sales of $284.7 Million PCS Sales Increase Year-Over-Year and Sequentially Second-Quarter GAAP Earnings per Share of $0.63 and Non-GAAP Earnings per Share of $0.75 Updates Sales and EPS Guidance for 2012 WILMINGTON, Mass. --(BUSINESS WIRE)--Aug.
First-Quarter Sales of $286.0 Million RMS Sales Increase 5.6%, and 6.5% in Constant Currency First-Quarter GAAP Earnings per Share of $0.54 and Non-GAAP Earnings per Share of $0.70 Reaffirms Sales and EPS Guidance for 2012 WILMINGTON, Mass. --(BUSINESS WIRE)--May.
Fourth-Quarter Sales of $291.0 Million and Full-Year 2011 Sales of $1.14 Billion Fourth-Quarter GAAP Earnings per Share of $0.55 and Non-GAAP Earnings per Share of $0.69 Full-Year GAAP Earnings per Share of $2.24 and Non-GAAP Earnings per Share Increase 29% to $2.56 Reaffirms 2012 Guidance
WILMINGTON, Mass. --(BUSINESS WIRE)--Dec. 14, 2011-- Charles River Laboratories International, Inc. (NYSE: CRL) today provided guidance for 2012 and updated guidance for 2011. James C. Foster , Chairman, President and Chief Executive Officer, said, “We made significant progress in 2011 on our four
- Sales of $277.6 Million - - GAAP Earnings per Share of $0.37 and Non-GAAP Earnings per Share of $0.57 - - Updates 2011 EPS Guidance - WILMINGTON, Mass., Nov 01, 2011 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of
- UC Davis, TCP, CHORI and Charles River Form DTCC Scientific Consortium - WILMINGTON, Mass., Sep 29, 2011 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that the DTCC, a consortium formed by the University of California Davis (UC Davis), Toronto
- Dr. Nancy Gillett Named Chief Scientific Officer; Dr. Davide Molho Appointed Corporate Executive Vice President and President, North American Operations; and Dr. Jörg Geller Promoted to Corporate Executive Vice President and President, European & Asian Operations - WILMINGTON, Mass., Aug 23, 2011
- Sales of $288.3 Million - - GAAP Earnings per Share of $0.66 and Non-GAAP Earnings per Share of $0.70 - - Raises 2011 Sales and EPS Guidance - WILMINGTON, Mass., Aug 02, 2011 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second
- Sales of $285.8 Million - - GAAP Earnings per Share of $0.65 and Non-GAAP Earnings per Share of $0.61 - - Reaffirms Sales and Non-GAAP EPS Guidance for 2011; Updates 2011 GAAP EPS Guidance - WILMINGTON, Mass., May 03, 2011 (BUSINESS WIRE) -- Charles River Laboratories International, Inc.
Agreement Expands Access to Pfizer's Pre-Competitive Research, Helping to Advance Basic Science WILMINGTON, Mass., Mar 03, 2011 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a marketing and distribution agreement with Pfizer
- Amends Credit Agreement To Add A $150 Million Term Loan - WILMINGTON, Mass., Feb 24, 2011 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has implemented a new accelerated stock repurchase (ASR) program to repurchase $150 million of common
Company Records Goodwill and Other Impairments of $395.0 Million, or $6.28 per Share Fourth-Quarter Sales of $281.7 Million and Full-Year 2010 Sales of $1.13 Billion Fourth-Quarter GAAP Loss per Share of $5.94 and Non-GAAP Earnings per Share of $0.60 Full-Year GAAP Loss per Share of $5.25 and
New Director Appointments Underscore Commitment to Four Key Company Initiatives WILMINGTON, Mass., Jan 24, 2011 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointments of Robert J. Bertolini and Richard F.
Intensifies Focus on Four Key Initiatives to Drive Shareholder Value Provides 2011 Financial Guidance WILMINGTON, Mass., Dec 14, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) shared today its outlook for its business, highlighting its unique portfolio in the
Sales of $276 Million GAAP Loss per Share of $0.40 Includes Transaction Termination Fee; Non-GAAP Earnings per Share of $0.45 Announces Actions Expected to Generate $40 Million of Cost Savings Reduces Sales and EPS Guidance for 2010 Increases Stock Repurchase Authorization to $750 Million
Exclusive Global Provider for Transposagen's p53 and Bcrp TGEM(TM) Knockout Rat Models WILMINGTON, Mass., Oct 13, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive, long-term marketing and distribution agreement
Amends Credit Agreement to Provide Up to $750 Million in Financing WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL - News) announced today that it has implemented an accelerated stock repurchase (ASR) program to repurchase $300 million of common stock,
Sales of $292 Million GAAP Earnings per Share of $0.22 and Non-GAAP Earnings per Share of $0.49 Reduces Sales and EPS Guidance for 2010 WILMINGTON, Mass., Aug 02, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of
Board of Directors Approves $500 Million Stock Repurchase Plan Special Stockholder Meeting Canceled Second-Quarter Earnings Release and Conference Call Rescheduled WILMINGTON, Mass., Jul 29, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc.
Advisory Service Recommends Charles River Shareholders Approve Stock Issuance to Complete Acquisition WILMINGTON, Mass., Jul 15, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that PROXY Governance, Inc., a proxy voting advisory service,
Combined Company Expects to Generate Annual Revenue Synergies of at Least $75 Million to $100 Million by 2013 WILMINGTON, Mass. & SHANGHAI, China, Jul 13, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc.(NYSE: CRL) and WuXi PharmaTech (NYSE:WX) today announced that they have
WILMINGTON, Mass., Jul 01, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, announced today that it has filed its definitive proxy statement with the
Downloadable version . $1.6 Billion Transaction Transforms CRO Landscape by Creating One Provider Delivering Services from Molecule Creation through First-in-Human Testing Leverages the Leading Chemistry and In Vivo Biology Franchises Expands Clients' Ability to Place Early-Stage Studies in North
Downloadable version . Sales of $297 Million GAAP Earnings per Share of $0.26 and Non-GAAP Earnings per Share of $0.45 WILMINGTON, Mass., Apr 26, 2010 (BUSINESS WIRE) --Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2010.
First preclinical contract research organization in China to receive certification WILMINGTON, Mass., Apr 15, 2010 (BUSINESS WIRE) --Charles River Laboratories, Inc. (NYSE: CRL), today announced the Company's Shanghai facility became the first preclinical laboratory in China to receive a
Downloadable version . Fourth-Quarter Sales of $295.4 Million and Full-Year 2009 Sales of $1.2 Billion Fourth-Quarter GAAP Earnings per Share of $0.27 and Non-GAAP Earnings per Share of $0.49 Full-Year GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.38 2010 Guidance of GAAP
Leaner Infrastructure Will Improve Operating Efficiency While Maintaining Ability to Meet Anticipated Upturn in Demand Reaffirms 2009 Sales Guidance and Expects Non-GAAP EPS to be Above Previous Guidance Range Company to Present at J.P. Morgan Healthcare Conference WILMINGTON, Mass., Jan 11, 2010
Downloadable version . Sales Decrease 13.1% to $297 Million GAAP Earnings per Share of $0.57 and Non-GAAP Earnings per Share of $0.65 Cost-Reduction Initiatives Now Expected to Total $40.0 Million of Savings in 2009 Reduces Sales and EPS Guidance for 2009 WILMINGTON, Mass. --(BUSINESS WIRE)--Nov.
Leading contract research organization achieves regulatory milestones WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 7, 2009-- Charles River Laboratories, Inc. (NYSE: CRL), today announced the Company’s new Shanghai facility received accreditation from the Association for Assessment and Accreditation of
Downloadable version . Sales Decrease 12.5% to $308 Million WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 4, 2009-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2009. For the quarter, net sales decreased 12.5% to $308.2 million from
Real H. Renaud to Retire by End of 2010 WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 1, 2009-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a succession plan for Research Models and Services (RMS) and enhancements to the Preclinical Services (PCS) and Sales organizations.
First-Quarter Sales Decrease 11% to $302 Million WILMINGTON, Mass. --(BUSINESS WIRE)--May. 5, 2009-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first-quarter of 2009. For the quarter, net sales decreased 10.7% to $301.5 million from $337.7 million
Expands Discovery and Imaging Services Through Additional Oncology Expertise WILMINGTON, Mass., Apr 03, 2009 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today the signing of an agreement to acquire the business and assets of Piedmont Research Center, LLC,
Downloadable version . WILMINGTON, Mass. --(BUSINESS WIRE)--Feb. 9, 2009-- Charles River Laboratories International, Inc. (NYSE: CRL): – Company Records Goodwill Impairment of $700.0 Million , or $10.43 per Share – – Fourth-Quarter GAAP Loss per Share of $9.91 Including the Charge, and Non-GAAP
WILMINGTON, Mass., Nov 19, 2008 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the promotion of Foster Jordan to Corporate Senior Vice President, Endotoxin & Microbial Detection Products. "With Foster's direction our in vitro solutions are market
Downloadable version . Third-Quarter Sales Increase 9.0% to $342 Million Third-Quarter GAAP EPS Increase 1.6% to $0.63 and Non-GAAP EPS Increase 10.1% to $0.76 Company Updates 2008 Guidance WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 5, 2008--Charles River Laboratories International, Inc.
WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 30, 2008--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that Dr. Deborah Kochevar, Dean of the Cummings School of Veterinary Medicine at Tufts University, was elected to the Company's Board of Directors. Dr.
New Facility Positions Company as Premier Preclinical CRO in China WILMINGTON, Mass.--(BUSINESS WIRE)--To support the growing demand from multinational pharmaceutical clients for outsourced drug development services, Charles River Laboratories International, Inc.
Marks Historic First in Conference History for an Independent Clinical Pharmacology Unit to Host the Meeting WILMINGTON, Mass.--(BUSINESS WIRE)--The Association of Clinical Pharmacology Units (ACPU), for the first time in its history, selected an independent CPU as the host for its 2008 Annual
Industry leader strengthens interface with customers worldwide WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today the promotion of Dr. Christophe Berthoux to the newly-created position of Executive Vice President, Global Sales and
Extends Discovery Services by Adding Oncology, Inflammation and Imaging Expertise WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 15, 2008--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired privately-held Molecular Imaging Research, Inc.
WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 9, 2008--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the acquisition of privately-held NewLab BioQuality AG (NewLab), a Dusseldorf, Germany-based provider of safety and quality control services to
Downloadable version . Second-Quarter Sales Increase 14.5% to $352 Million Second-Quarter GAAP EPS Increase 29% to $0.71 and Non-GAAP EPS Increase 23% to $0.79 Raising 2008 Sales and Non-GAAP EPS Guidance, GAAP EPS Guidance Lowered Agreement Signed to Acquire NewLab BioQuality AG Increases Stock
Leading CRO expands footprint in Maryland to support customer demand and RMS geographic growth WILMINGTON, Mass.--(BUSINESS WIRE)--July 29, 2008--In response to increasing demand and to better serve its customer the National Cancer Institute (NCI), Charles River Laboratories International, Inc.
Downloadable version . First-Quarter Sales Increase 16% to $338 Million Due to Strong Customer Demand First-Quarter GAAP EPS of $0.64 and Non-GAAP EPS of $0.72 Reaffirms Guidance for 2008 WILMINGTON, Mass., May 06, 2008 (BUSINESS WIRE) -- Charles River Laboratories International, Inc.
Downloadable version . Strong Customer Demand Drives Double-Digit Sales and Earnings Growth Fourth-Quarter Sales Increase 17.0% and Full Year Rises 16.3% to $1.23 Billion Fourth-Quarter GAAP EPS of $0.55 and Non-GAAP EPS of $0.65 2007 GAAP EPS of $2.29 and Non-GAAP EPS of $2.62 Exceed Company
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 12, 2007--Charles River Laboratories International, Inc. (NYSE:CRL) today reaffirmed its previously announced guidance for 2007 and provided guidance for 2008. 2007 Guidance Reaffirmed For 2007, Charles River is maintaining its previously announced sales
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 3, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that Richard Reese, Chairman and Chief Executive Officer at Iron Mountain Incorporated (NYSE: IRM) was elected to the organization's Board of Directors. Mr.
Downloadable version . Sales Increase 18.6% to $314 Million GAAP EPS Increase 34.0% to $0.63 Non-GAAP EPS Increase 21.1% to $0.69 Company Increases 2007 Sales and EPS Guidance WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 5, 2007--Charles River Laboratories International, Inc.
WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 2, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the promotions of three industry veterans, including: Brian Bathgate, Ph.D., to Corporate Senior Vice President and President, European Preclinical Services, Jorg Geller,
Seasoned industry veteran brings 25 years of operational and scientific expertise WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 24, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of biopharmaceutical entrepreneur Nancy T. Chang, Ph.D.
WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 27, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to build a new facility in Sherbrooke, Quebec, to support the company's expanding Preclinical Services business.
Downloadable version . Sales Increase 14.8% to $307 Million GAAP EPS Increase 19.6% to $0.55 Non-GAAP EPS Increase 10.3% to $0.64 2007 Sales Guidance Increased and EPS Guidance Narrowed to Upper End of Range Increases Stock Repurchase Authorization by $100 Million WILMINGTON, Mass.--(BUSINESS
WILMINGTON, Mass.--(BUSINESS WIRE)--June 19, 2007--James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories International, Inc. (NYSE: CRL), was named one of the New England region's 2007 Entrepreneurs of the Year by Ernst & Young LLP at an awards ceremony held
WILMINGTON, Mass.--(BUSINESS WIRE)--June 14, 2007--Charles River Laboratories International, Inc. (NYSE:CRL) announced today the closing of its previously announced joint venture with Shanghai BioExplorer Co., Ltd. to form Charles River Laboratories Greater China, Preclinical Services Shanghai
Downloadable version . First-Quarter Sales Increase 14.6% to $291 Million First-Quarter GAAP EPS Increase 41% to $0.55 First-Quarter Non-GAAP EPS Increase 33.3% to $0.64 Reaffirms Guidance for 2007 WILMINGTON, Mass.--(BUSINESS WIRE)--May 8, 2007--Charles River Laboratories International, Inc.
WILMINGTON, Mass.--(BUSINESS WIRE)--April 24, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) announced today the appointment of Cheri Walker, Ph.D. to the role of Corporate Senior Vice President, Corporate Development, effective April 24, 2007. Dr.
Signs Joint Venture Agreement with Chinese Partner Plans to Construct 50,000-Square-Foot Preclinical Facility in Shanghai WILMINGTON, Mass.--(BUSINESS WIRE)--March 23, 2007--Charles River Laboratories International, Inc. (NYSE:CRL) announced today the expansion of its global footprint in Asia as
WILMINGTON, Mass., Mar 16, 2007 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) announced today the appointment of Stephanie Wells to the role of Corporate Senior Vice President, Marketing and Chief Marketing Officer, effective March 12, 2007.
Dr. Craig Mello Keynote Speaker at Open House WILMINGTON, Mass.--(BUSINESS WIRE)--March 6, 2007--Charles River Laboratories International, Inc. (NYSE:CRL) hosted a customer open house at its new, state-of-the-art preclinical services facility in Shrewsbury, Massachusetts.
Downloadable version . Fourth-Quarter Sales of $272 Million and Full-Year Sales of $1.06 Billion Fourth-Quarter GAAP EPS of $0.47 and Non-GAAP EPS of $0.58 2006 GAAP EPS of $1.79 and Non-GAAP EPS of $2.20 Reaffirms Guidance for 2007 WILMINGTON, Mass.--(BUSINESS WIRE)--Feb.
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 3, 2007--Charles River Laboratories International, Inc. (NYSE:CRL) announces that its portable endotoxin testing system, the Endosafe(R) - PTS(TM), was recently launched into space aboard the space shuttle Discovery and successfully reached the International
Non-GAAP EPS Guidance Adjusted for Amortization Expense WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 13, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) today reaffirmed its previously announced GAAP guidance for 2006, adjusted its non-GAAP earnings per diluted share guidance to exclude
First Clinical Pharmacology Unit to Receive Partner Designation and to Implement Mortara's 12-Lead Telemetry System TACOMA, Wash.--(BUSINESS WIRE)--Dec. 6, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that its Clinical Services -- Northwest Kinetics unit has
WILMINGTON, Mass., Nov 21, 2006 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) will issue a press release to provide 2007 financial guidance on Wednesday, December 13, 2006, after the market closes. A conference call has been scheduled to discuss the guidance on
WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 13, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster will present at the Credit Suisse Healthcare Conference in Phoenix, Arizona on Wednesday, November 15th,
Downloadable version . Net Sales Increase 9.0% Company on Target to Achieve Previously Announced Sales and Earnings Guidance for 2006 WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 6, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) today reported third-quarter and year-to-date 2006
WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 30, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired privately held Tacoma, Washington-based Northwest Kinetics, Inc. for $29.5 million dollars. The acquisition establishes a Phase I clinical services
WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 25, 2006--(NYSE:CRL) Charles River Laboratories, a leading contract research organization worldwide, is dramatically enhancing its technological capabilities across its entire business. In the life sciences industry which is driven by information, Charles
WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 5, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter 2006 financial results on Monday, November 6, 2006, after the market closes. A conference call has been scheduled to discuss the results on Tuesday, November 7,
WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 22, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster will present at the UBS Global Life Sciences Conference in New York on Tuesday, September 26th, at 11:30
WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 22, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has been awarded a ten year, $111.6 million contract by the National Cancer Institute (NCI), more than doubling the size of its current contract with NCI.
WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 11, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster will present at the Bear Stearns 19th Annual Healthcare Conference in New York on Tuesday, September
WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 5, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster will present at the Thomas Weisel Partners Healthcare Conference in Boston, on Thursday, September 7th,
WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 16, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) today completed the previously announced sale of its Phase II-IV Clinical Services business to Kendle International Inc. The sale of the business was completed in accordance with the terms
Downloadable version . Net Sales Increase of 6.8% on Preclinical Services Growth of 14.1% GAAP EPS of $0.46 and Non-GAAP EPS of $0.57 Non-GAAP EPS Increase 21% from $0.47 in First Quarter of 2006 Benefit of Strategic Initiatives Drives Operating Efficiency WILMINGTON, Mass.--(BUSINESS WIRE)--Aug.
WILMINGTON, Mass.--(BUSINESS WIRE)--July 18, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) has received FDA approval that allows for the sale and marketing of the first portable endotoxin test system, the Endosafe-PTS(TM). The patented Endosafe-PTS(TM) is used to detect endotoxin
WILMINGTON, Mass.--(BUSINESS WIRE)--July 11, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2006 financial results on Tuesday, August 8, 2006, after the market closes. A conference call has been scheduled to discuss the results on Wednesday, August 9,
WILMINGTON, Mass.--(BUSINESS WIRE)--June 26, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Executive Vice President and Chief Financial Officer Thomas F. Ackerman will present at the Jefferies Life Sciences Conference in New York, on Tuesday, June 27th, at
WILMINGTON, Mass.--(BUSINESS WIRE)--June 12, 2006--Charles River Laboratories International, Inc. (NYSE: CRL), today announced the closing of its sale of $300 million principal amount of Convertible Senior Notes due 2013 in an offering to qualified institutional buyers pursuant to Rule 144A under
WILMINGTON, Mass.--(BUSINESS WIRE)--June 12, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Executive Vice President and Chief Financial Officer Thomas F. Ackerman will present at the Goldman Sachs 27th Annual Global Healthcare Conference in Dana Point,
WILMINGTON, Mass., Jun 06, 2006 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL), today announced the pricing of $300 million principal amount of Convertible Senior Notes due 2013 in an offering to qualified institutional buyers pursuant to Rule 144A under the
WILMINGTON, Mass.--(BUSINESS WIRE)--June 5, 2006--Charles River Laboratories International, Inc. (NYSE: CRL), today announced its intention to offer, subject to market and other conditions, $300 million principal amount of Convertible Senior Notes due 2013 in a private offering to qualified
WILMINGTON, Mass.--(BUSINESS WIRE)--May 15, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Executive Vice President and Chief Financial Officer Thomas F. Ackerman will present at the Bank of America Health Care Conference 2006 in Las Vegas, NV, on Wednesday,
Downloadable version . WILMINGTON, Mass.--(BUSINESS WIRE)--May 9, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) today reported first-quarter 2006 financial results and announced that it has entered into a definitive agreement with Kendle International Inc.
WILMINGTON, Mass.--(BUSINESS WIRE)--April 18, 2006--Charles River Laboratories International, Inc. (NYSE: CRL), a premier global provider of solutions that advance the drug discovery and development process, announces that it has adopted the OpenArray(TM) SNP Genotyping System from BioTrove.
WILMINGTON, Mass.--(BUSINESS WIRE)--April 12, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2006 financial results on Tuesday, May 9, 2006, after the market closes. A conference call has been scheduled to discuss the results on Wednesday, May 10, 2006,
WILMINGTON, Mass.--(BUSINESS WIRE)--March 27, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) (Charles River) today announced the appointment of Nicholas Ventresca in the role of Corporate Senior Vice President, Information Technology and Chief Information Officer, effective April
WILMINGTON, Mass.--(BUSINESS WIRE)--March 22, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) (Charles River), a global provider of solutions that advance the drug discovery and development process today announced that they have entered into a licensing agreement with Washington
WILMINGTON, Mass.--(BUSINESS WIRE)--March 8, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster will present at the Lehman Brothers Ninth Annual Global Healthcare Conference in Miami, Florida, on
WILMINGTON, Mass.--(BUSINESS WIRE)--March 6, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster and Executive Vice President and Chief Financial Officer Thomas F.
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 10, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster and Executive Vice President and Chief Financial Officer Thomas F.
Downloadable version . Q4 Sales Reach $291 Million and 2005 Sales Exceed $1.1 Billion Q4 GAAP Earnings Per Share of $0.69 and $0.59 on a Non-GAAP Basis 2005 GAAP Earnings Per Share of $1.96 and $2.29 on a Non-GAAP Basis Reaffirms 2006 Guidance WILMINGTON, Mass.--(BUSINESS WIRE)--Feb.
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 16, 2006--Charles River Laboratories International, Inc. (NYSE: CRL), a premier global provider of solutions that advance the drug discovery and development process, today announced that John C. Ho, M.D. will join the Company effective January 9, 2006, as
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 9, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2005 financial results on Wednesday, February 8, 2006, after the market closes. A conference call has been scheduled to discuss the results on
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 9, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) (Charles River), a premier global provider of solutions that advance the drug discovery and development process, announces that it has established a worldwide collaboration with Deltagen,
WILMINGTON, Mass., Jan 06, 2006 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster and Corporate Executive Vice President and Chief Financial Officer Thomas F.
WILMINGTON, Mass. and AUSTIN, Texas--(BUSINESS WIRE)--Jan. 5, 2006--Charles River Laboratories International, Inc. (NYSE:CRL) (Charles River), a global provider of solutions that advance the drug discovery and development process, and Luminex Corporation (NASDAQ: LMNX) today announced that they
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 14, 2005--Charles River Laboratories International, Inc. (NYSE:CRL) in conjunction with its analyst meeting held today in New York, provided guidance for 2006 and reaffirmed its previously announced guidance for the fourth quarter and full year 2005.
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 12, 2005--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has accelerated the vesting of outstanding options previously awarded to certain officers and employees. As a result of the acceleration, the Company expects to take
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 12, 2005--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that management will hold a meeting for the investment community on Wednesday, December 14, 2005. Investors as well as the general public are invited to listen to a live
WILMINGTON, Mass., Nov 14, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster will present at the Credit Suisse First Boston Healthcare Conference in Phoenix, Arizona, on Wednesday,
WILMINGTON, MA, November 4, 2005 – The Research Models and Services division of Charles River Laboratories International, Inc. (NYSE:CRL) (Charles River) and Rules-Based Medicine, Inc. (RBM) today announced the collaborated extension and expansion of their exclusive worldwide agreement.
Corporate Vice President Appointments in U.S & Canadian Preclinical Services, Corporate Investor Relations and Research Models Services & Operations WILMINGTON, MA, October 28, 2005 – Charles River Laboratories International, Inc. (NYSE:CRL)announces two Executive Vice President appointments and
Downloadable version . Increases Stock Repurchase Authorization to $100 Million WILMINGTON, Mass., Oct 27, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) today reported third-quarter 2005 financial results. Net sales for the third quarter of 2005 increased 55.6%
WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 17, 2005--The Clinical Services division of Charles River Laboratories International, Inc. (NYSE:CRL) (Charles River) and DataLabs are pleased to announce an EDC partnership to utilize the latest version of DataLabsXC(TM) electronic clinical data management
WILMINGTON, Mass., Oct 05, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter 2005 financial results on Thursday, October 27, 2005, after the market closes. A conference call has been scheduled to discuss the results on Friday, October 28,
WILMINGTON, Mass., Sep 29, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that David J. Elliott will join the Company effective October 31, 2005 in the role of Corporate Controller. Mr. Elliott joins Charles River from Cabot Corporation where he
WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 8, 2005--Charles River Laboratories International, Inc. (NYSE:CRL) today said that based upon its current forecast, it expects that for the third quarter ending September 24, 2005, at current exchange rates, its net sales growth and earnings per diluted
WILMINGTON, Mass., Sep 01, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that senior management will present at three conferences in September 2005. On Thursday, September 8th, at 9:45 a.m. ET, Chairman, President and Chief Executive Officer
Downloadable version . Sales Increase 57.3% to $283 million GAAP Earnings Per Share of $0.44 and $0.59 on a Non-GAAP Basis Company Reaffirms Guidance for 2005 on Continuing Strong Demand for Outsourced Services Board of Directors Approves $50 Million Stock Repurchase Plan WILMINGTON,
WILMINGTON, Mass., Jul 05, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2005 financial results on Thursday, July 28, 2005, after the market closes. A conference call has been scheduled to discuss the results on Friday, July 29, 2005,
WILMINGTON, Mass.--(BUSINESS WIRE)--June 13, 2005--Charles River Laboratories, Inc. (NYSE: CRL) announces that James C. Foster, Chairman, President and CEO of the Company will be ringing the bell to close trading on the New York Stock Exchange on Monday, June 13, 2005, at 4 p.m. EDT.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Corporate Senior Vice President and Chief Financial Officer Thomas F. Ackerman will present at the Goldman Sachs 26th Annual Global Healthcare Conference in Dana Point, CA, on Wednesday, June 15th, at 9:40 a.m. PDT.
Downloadable version . Sales Increase 59% to $274 million GAAP Earnings Per Share of $0.40 and $0.55 on a Non-GAAP Basis Company Reaffirms Guidance for 2005 on Continuing Strong Demand for Outsourced Services WILMINGTON, Mass.--(BUSINESS WIRE)--May 3, 2005-- Charles River Laboratories
WILMINGTON, Mass., Apr 25, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that management will present at two conferences in May 2005. On Wednesday, May 11th, at 10:15 a.m. CDT, Chairman, President and Chief Executive Officer James C.
WILMINGTON, Mass., April 6 /PRNewswire-FirstCall/ -- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2005 financial results on Tuesday, May 3, 2005, after the market closes. A conference call has been scheduled to discuss the results on Wednesday, May 4, 2005,
WILMINGTON, Mass.--(BUSINESS WIRE)--March 30, 2005--Charles River Laboratories International, Inc. (NYSE: CRL) today reiterated that redemption of its $185 million, 3.50% Senior Convertible Debentures due February 1, 2022 is not expected to affect its previously disclosed earnings per share
WILMINGTON, Mass.--(BUSINESS WIRE)--March 28, 2005--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has called for redemption all of its $185 million, 3.50% Senior Convertible Debentures due February 1, 2022. Notices of redemption are being mailed to holders of
WILMINGTON, Mass., Mar 1, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster will present at the SG Cowen 25th Annual Health Care Conference in Boston, Massachusetts, on Tuesday,
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 14, 2005--In BW6332 issued Feb. 14, 2005: In the Condensed Consolidated Statements of Income (Unaudited) Table, the "diluted" line under the "Earnings per common share section", is corrected to read: Three Months Ended Twelve Months Ended
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2005--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster will present at the UBS 2005 Global Healthcare Services Conference in New York, N.Y., on Wednesday,
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 18, 2005--Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2004 financial results on Monday, February 14, 2005, after the market closes. A conference call has been scheduled to discuss the results on
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 3, 2005--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F.
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 15, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) in conjunction with its analyst meeting held today in New York, reaffirmed its previously announced guidance for the fourth-quarter and full-year 2004 and for 2005.
- Integration Related Organizational Changes Align Management and Strategy - - Proteomics Joint Venture To Close - WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 8, 2004-- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that in connection with the integration of Charles River
Jody Acford to Join Charles River as Corporate Senior Vice President, General Counsel and Corporate Secretary WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 1, 2004-- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Dennis Shaughnessy, Senior Vice President, Corporate
WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 1, 2004--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that management will present at two conferences in November 2004. On Wednesday, November 17th, at 3:45 a.m. ET (9:45 a.m. UTC/GMT+1), Senior Vice President and Chief
Downloadable version . Sales Increase 16% and Operating Income Increases 27% Operating Margin Reaches a Record 24.6% Earnings Per Share Rise 28% to $0.51 WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 28, 2004--Charles River Laboratories International, Inc.
WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 20, 2004--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has completed its merger with Inveresk Research Group, Inc. (NASDAQ: IRGI). The transaction was approved by shareholders of each company at special meetings held
WILMINGTON, Mass., Sep 28, 2004 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter financial results on Thursday, October 28, 2004, after the market closes. A conference call has been scheduled to discuss the results on Friday, October 29, 2004,
WILMINGTON, Mass. & CARY, N.C., Sep 8, 2004 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) and Inveresk Research Group (NASDAQ:IRGI) announced today that each company will hold a special meeting of shareholders on Wednesday, October 20, 2004.
WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 2, 2004--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that management will present at two conferences in September 2004. On Thursday, September 9th, at 10:00 a.m. EDT, Chairman, President and Chief Executive Officer James C.
WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 10, 2004--On August 4, 2004, Charles River Laboratories International, Inc. (NYSE:CRL) disclosed in its second-quarter report on Form 10-Q that as a result of the planned merger with Inveresk Research Group, Inc., management anticipated that the 2006 revenue
Downloadable version . - Sales Increase 17% and Operating Income Increases 26% - - Operating Margin Reaches a Record 24.5% - - Earnings Per Share Rise 24% to $0.52 - WILMINGTON, Mass.--(BUSINESS WIRE)--July 28, 2004-- Charles River Laboratories International, Inc.
WILMINGTON, Mass., or CARY, N.C., July 21 /PRNewswire-FirstCall/ -- Charles River Laboratories International, Inc. (NYSE: CRL) and Inveresk Research Group (Nasdaq: IRGI) announced today that the Federal Trade Commission has granted early termination of the waiting period required by the
WILMINGTON, Mass.--(BUSINESS WIRE)--July 6, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter financial results on Wednesday, July 28, 2004, after the market closes. A conference call has been scheduled to discuss the results on Thursday, July 29, 2004, at
WILMINGTON, Mass.--(BUSINESS WIRE)--July 1, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) today announced that for the second quarter of 2004, at current exchange rates, the Company now expects revenue growth of approximately 15% over the second quarter of 2003, compared to
WILMINGTON, Mass. & CARY, N.C.--(BUSINESS WIRE)--July 1, 2004--Charles River Laboratories International, Inc. (NYSE: CRL) and Inveresk Research Group, Inc. (NASDAQ: IRGI) - High-End Products and Services from Discovery Through the Clinic - - Creates Strategic Platform for Growth - Charles River
WILMINGTON, Mass., Jun 4, 2004 (BUSINESS WIRE) -- Charles River Laboratories International Inc. (NYSE:CRL), a leading provider of pre-clinical research products and services to pharmaceutical and biotechnology companies as well as academia and government announces the election of Linda McGoldrick
WILMINGTON, Mass.--(BUSINESS WIRE)--May 24, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Management will present at two conferences in June 2004. On Wednesday, June 9th, at 9:00 a.m. PDT, Chairman, President and Chief Executive Officer James C.
WILMINGTON, Mass.--(BUSINESS WIRE)--May 24, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Management will hold a meeting for the investment community on Wednesday, June 2, 2004. Investors as well as the general public are invited to listen to a live webcast of
Downloadable version . WILMINGTON, Mass.--(BUSINESS WIRE)--April 28, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) today reported a 13.5% increase in first-quarter 2004 net sales, to $172.6 million from $152.1 million reported in the first quarter of 2003.
WILMINGTON, Mass.--(BUSINESS WIRE)--April 27, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Management will present at three conferences in May 2004. On Tuesday, May 4th, at 11:25 a.m. CDT, Chairman, President and Chief Executive Officer James C.
WILMINGTON, Mass.--(BUSINESS WIRE)--April 1, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter financial results on Wednesday, April 28, 2004, after the market closes. A conference call has been scheduled to discuss the results on Thursday, April 29, 2004,
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 25, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Management will present at two conferences in March 2004. On Thursday, March 4th, at 10:15 a.m. EST, Chairman, President and Chief Executive Officer James C.
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 10, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) today reported a 9.2% increase in fourth-quarter 2003 net sales, to $156.0 million from $142.9 million reported in the fourth quarter of 2002.
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 12, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2003 financial results on Tuesday, February 10, 2004, after the market closes. A conference call has been scheduled to discuss the results on
WILMINGTON, Mass., Jan 12, 2004 (BUSINESS WIRE) -- Charles River Laboratories' (NYSE:CRL) Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F. Ackerman will present on Tuesday, January 13, at the JPMorgan 22nd Annual
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 8, 2004--Charles River Laboratories International, Inc. (NYSE:CRL) today announced that it has acquired River Valley Farms, a privately-held medical device contract research business located near Minneapolis, Minnesota, one of the major cardiovascular
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 30, 2003--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F.
WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 13, 2003--Charles River Laboratories (NYSE:CRL), a leading provider of pre-clinical research products and services to pharmaceutical and biotechnology companies, announces the formation of its Scientific Advisory Board.
WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 29, 2003--Charles River Laboratories International, Inc. (NYSE:CRL) today reported third-quarter 2003 net sales of $151.2 million, a 7.0% increase over the $141.4 million reported in the third quarter of 2002. Net income for the third quarter of 2003
WILMINGTON, Mass.--(BUSINESS WIRE)--Sept. 2, 2003--Charles River Laboratories International, Inc. (NYSE:CRL) today announced updated guidance for the third-quarter and full-year 2003. For the third quarter, at current exchange rates, the Company now expects revenue growth in a range of 6-9% over
--(BUSINESS WIRE)-- Charles River Laboratories International Inc. (NYSE:CRL), a leading provider of pre-clinical research products and services to pharmaceutical and biotechnology companies, launched the Endosafe(R)-PTS today. The PTS is a portable test system based on the Limulus Amebocyte Lysate
WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 14, 2003-- Handheld Endotoxin Detection System Gives Fast, Quantitative Results with Ease Charles River Laboratories International, Inc. (NYSE: CRL), a leading provider of pre-clinical research products and services to pharmaceutical and biotechnology
WILMINGTON, Mass.--(BUSINESS WIRE)--July 29, 2003-- Second-Quarter Sales Increase 13% and Operating Income Increases 15%; Earnings Per Share Rise 24% to $0.42 Charles River Laboratories International, Inc. (NYSE:CRL) today reported second-quarter 2003 net sales of $154.4 million, a 13.1% increase
WILMINGTON, Mass.--(BUSINESS WIRE)--June 30, 2003--Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2003 financial results on Tuesday, July 29, 2003, after the market closes. A conference call has been scheduled to discuss the results on Wednesday, July 30,
WILMINGTON, Mass.--(BUSINESS WIRE)--May 21, 2003--Charles River Laboratories International, Inc. (NYSE:CRL), a leading provider of pre-clinical research products and services to pharmaceutical and biotechnology companies, announced that it has been ranked fourth overall in The Boston Globe 15th
- First-Quarter Sales Increase 13.7% and Operating Income Rises 19.1% - WILMINGTON, Mass.--(BUSINESS WIRE)--April 30, 2003-- Charles River Laboratories International, Inc. (NYSE:CRL) today reported first-quarter 2003 net sales of $152.1 million, a 13.7% increase over the $133.8 million reported in
WILMINGTON, Mass., Apr 28, 2003 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL), a leading provider of pre-clinical research products and services to pharmaceutical and biotechnology companies, announced that it has been ranked 3rd in the Boston Herald Superstar 10
WILMINGTON, Mass.--(BUSINESS WIRE)--April 7, 2003-- - Services to Speed Availability of Genetically-Modified Research Models - Charles River Laboratories International, Inc. (NYSE:CRL), a leading provider of pre-clinical research products and services to biopharmaceutical and biotechnology
WILMINGTON, Mass.--(BUSINESS WIRE)--April 3, 2003--Charles River Laboratories International, Inc. (NYSE:CRL) and Proteome Systems Ltd. are pleased to announce the opening of a new contract laboratory dedicated to proteomic research services. Charles River Proteomic Services, Inc.
WILMINGTON, Mass., Mar 17, 2003 (BUSINESS WIRE) -- Charles River Laboratories' (NYSE:CRL) Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F. Ackerman will present on Tuesday, March 18, at the S.G Cowen 23rd Annual Health
WILMINGTON, Mass., Mar 7, 2003 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F.
WILMINGTON, Mass., Feb 26, 2003 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) announced that at its Board of Directors meeting today, George E. Massaro was elected to the Board. Mr. Massaro is the seventh independent member of Charles River's eight-person Board.
WILMINGTON, Mass., Feb 20, 2003 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) announced today Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F.
WILMINGTON, Mass., Feb 3, 2003 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) today reported fourth-quarter 2002 income before extraordinary item of $17.5 million, a 58.3% increase over the $11.1 million reported in the fourth quarter of 2001.
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 21, 2003--Charles River Laboratories International, Inc. (NYSE:CRL) announced today Senior Vice President and Chief Financial Officer Thomas F. Ackerman will discuss the Company's business outlook at the UBS Warburg Global Healthcare Services Conference in
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 6, 2003--Charles River Laboratories International, Inc. (NYSE:CRL) today announced that it has increased its ownership interest in Charles River Japan, a joint venture with Ajinomoto Co., Inc. Charles River purchased 404,321 shares of Charles River Japan for
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 6, 2003--Charles River Laboratories' (NYSE:CRL) Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F. Ackerman will present on Tuesday, January 7, at the JPMorgan H&Q 21st Annual
WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 16, 2002--Charles River Laboratories International, Inc. (NYSE:CRL) today announced that at its meeting on December 10, 2002, the Board of Directors voted to promote Real H. Renaud to the newly-created position of Executive Vice President and General
WILMINGTON, Mass., Oct 29, 2002 (BUSINESS WIRE) -- Third-Quarter Income Before Extraordinary Item Up 60% and EPS Up 50% on Net Sales Increase of 14% Total Year 2002 EPS Guidance Raised to $1.41-$1.43 Strong Sales and EPS Growth Expected in 2003 Douglas E.
WILMINGTON, Mass., Oct 11, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Forbes Magazine has named James C. Foster, its Chairman and CEO, as "Entrepreneur of the Year" in its October 28 issue. Mr.
WILMINGTON, Mass., Oct 7, 2002 (BUSINESS WIRE) -- Charles River Laboratories' (NYSE:CRL) Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F. Ackerman will present on Tuesday, October 8, at the UBS Warburg Global Life
WILMINGTON, Mass. & SYDNEY, Australia, Oct 2, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) and Proteome Systems Ltd announced today the signing of an agreement to establish a joint venture that will provide leading edge proteomics testing and analysis services
WILMINGTON, Mass., Oct 1, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has acquired privately-held Springborn Laboratories, Inc. (SLI). SLI is a leading provider of testing services for pre-clinical drug discovery and development, principally
WILMINGTON, Mass., Oct 1, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) has scheduled a conference call to discuss third-quarter 2002 financial results on October 30, 2002 at 8:30 a.m. Eastern Standard Time. Charles River will release third-quarter 2002 results
WILMINGTON, Mass., Sep 12, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Chairman, President and CEO James C. Foster and Senior Vice President and CFO Thomas F. Ackerman will discuss the company's business outlook at the Bear Stearns 15th
WILMINGTON, Mass., Sep 9, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL), today announced the appointments of two senior executives in the areas of Drug Discovery and Development and Investor Relations. Dr. Nancy Gillett Appointed Corporate Vice President, Drug
WILMINGTON, Mass., Sep 4, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) has introduced an in vitro test kit that provides a new, non-animal method for detecting harmful microbial contamination in drugs, medical devices, and a wide range of other therapeutic
WILMINGTON, Mass., Sep 3, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) has been added to the Standard & Poor's S&P MidCap 400 Stock Index. The S&P MidCap 400 Index is comprised of US publicly traded companies, based on market value, liquidity and industry
WILMINGTON, Mass., Jul 30, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) achieved strong growth in sales and earnings for the second quarter of 2002. The Company's second quarter sales increased 17% over the prior year, driven by strong growth in customer demand
WILMINGTON, Mass., Jul 3, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) ("Charles River") has scheduled a conference call to discuss second quarter 2002 financial results. The call is scheduled to take place on July 31, 2002 at 8:30 a.m. Eastern Daylight Time.
WILMINGTON, Mass., Jun 14, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE:CRL) today announced that it has retired the remaining balance of its indebtedness related to the September 1999 management-led leveraged buy-out transaction.
WILMINGTON, Mass., Jun 10, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE:CRL) today announced that it has acquired privately-held Biological Laboratories Europe Ltd. ("BioLabs"), a leading drug discovery and development services company located in Western Ireland.
WILMINGTON, Mass., May 21, 2002 (BWHealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has been named "Company of the Year" by The Boston Globe in its 2002 ranking of the best-performing public companies in Massachusetts.
WILMINGTON, Mass., May 1, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) achieved strong growth in sales and earnings for the first quarter of 2002. The Company's first quarter sales increased 35% over the prior year, driven by strong growth in customer demand
WILMINGTON, Mass., Apr 10, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) ("Charles River") has scheduled a conference call to discuss first quarter 2002 financial results. The call is scheduled to take place on May 2, 2002 at 8:30 a.m. Eastern Daylight Time.
WILMINGTON, Mass., Feb 21, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (CRL:NYSE) announced today that the lead investor group in its September 1999 management-led leveraged buy-out transaction, Credit Suisse First Boston's (CSFB) DLJ Merchant Banking Group (DLJMB), has
WILMINGTON, Mass., Feb 12, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today the consideration to be paid by its wholly-owned subsidiary, Charles River Laboratories, Inc., in its cash tender offer for any and all of its outstanding 13.5% Senior
WILMINGTON, Mass., Feb 6, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) and its wholly-owned subsidiary, Charles River Laboratories, Inc., achieved strong growth in sales and earnings for the fourth quarter and for the full year 2001.
WILMINGTON, Mass., Jan 29, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its wholly owned subsidiary, Charles River Laboratories, Inc., has received consents from the requisite number of holders of its 13.50% Senior Subordinated Notes due
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 23, 2002--Charles River Laboratories International, Inc. (NYSE: CRL) has scheduled a conference call to discuss fourth quarter 2001 financial results. The call will take place on Thursday, February 7, 2002 at 8:30 a.m. Eastern Standard Time.
WILMINGTON, Mass., Jan 17, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the private placement of $175 million of Senior Convertible Debentures. The Debentures will accrue interest at an annual rate of 3.50% that will be payable semiannually.
WILMINGTON, Mass.--(BW HealthWire)--Jan. 15, 2002--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its wholly-owned subsidiary, Charles River Laboratories, Inc., has commenced a cash tender offer for any and all of its outstanding 13.5% Senior Subordinated Notes due
WILMINGTON, Mass., Jan 15, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced its intention, subject to market and other conditions, to offer in a private placement approximately $150 million in Senior Convertible Debentures.
WILMINGTON, Mass., Jan 14, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE:CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., today announced that it has acquired DakDak Photoaging Technologies, Inc.
WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 7, 2002--Charles River Laboratories International, Inc. (NYSE: CRL - news) announced today that it is raising its previous guidance on estimated earnings per share performance for the recently completed fourth quarter.
WILMINGTON, Mass., Jan 4, 2002 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that Chairman and CEO James C. Foster will be presenting at the 20th Annual JPMorgan H&Q Healthcare Conference in San Francisco, California on Wednesday, January 9, 2002 at
WILMINGTON, Mass., Dec 13, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (CRL:NYSE) announced today the resignations of four representatives of Credit Suisse First Boston's DLJ Merchant Banking group who have served on Charles River's Board of Directors since the September
WILMINGTON, Mass., Dec 5, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (CRL:NYSE) announced today that the lead investor group in its September 1999 management-led leveraged buy-out transaction, Credit Suisse First Boston's DLJ Merchant Banking Group (DLJMB), has
WILMINGTON, Mass., Nov 8, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (CRL:NYSE) announced today that the lead investor group in its September 1999 management-led leveraged buy-out (LBO) transaction, Credit Suisse First Boston's DLJ Merchant Banking Group (DLJMB) group,
WILMINGTON, Mass., Oct 31, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE:CRL), reported today that sales increased 64% in the third quarter of 2001 compared to the third quarter of 2000. Sales for this year's third quarter were $123.7 million, a $48.1 million increase
WILMINGTON, Mass.--(BW HealthWire)--Sept. 28, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) ("Charles River") has scheduled a conference call to discuss third quarter 2001 financial results. The call is scheduled to take place on November 1, 2001 at 8:30 a.m.
WILMINGTON, Mass. & MILWAUKEE, Sep 27, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) and the Medical College of Wisconsin in Milwaukee today announced that the organizations have entered into an agreement to distribute novel "consomic" rat models developed at
WILMINGTON, Mass., Sep 25, 2001 (BW HealthWire) -- Charles River Laboratories, Inc. (NYSE: CRL) has been awarded a five-year, $24 million contract to manage a portion of the research support operations of the National Cancer Institute's Frederick Cancer Research and Development Center.
WILMINGTON, Mass., Sep 24, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is raising its previous guidance on estimated earnings per share performance for the third quarter. The Company estimates third quarter 2001 earnings per fully
WILMINGTON, Mass.--(BW HealthWire)--Aug. 2, 2001--Charles River Laboratories International, Inc. (NYSE:CRL), reported today that sales increased 51% in the second quarter of 2001 compared to the second quarter of 2000. Sales for this year's second quarter were $116.8 million, a $39.4 million
WILMINGTON, Mass.--(BW HealthWire)--July 30, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) ("Charles River") have scheduled a conference call to discuss second quarter 2001 financial results. The call is scheduled to take place on August 3, 2001 at 8:30 a.m.
WILMINGTON, Mass.--(BW HealthWire)--July 20, 2001--Charles River Laboratories International, Inc. (NYSE:CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., today announced the completion of the acquisition of Genetic Models, Inc. (GMi).
WILMINGTON, Mass.--(BW HealthWire)--July 20, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it priced its public offering of 8,000,000 shares of common stock (excluding the underwriters' over-allotment option to purchase an additional 1,200,000 shares of
WILMINGTON, Mass. & BAR HARBOR, Maine, Jul 13, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., and The Jackson Laboratory today announced that the organizations have entered into a cooperative
WILMINGTON, Mass. & RICHMOND, Calif., Jul 11, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., and Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that they have entered into a
WILMINGTON, Mass., Jul 5, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE: CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., today announced that it has entered into a technology partnership agreement with Advanced Cell Technology, Inc.
WILMINGTON, Mass., Jul 5, 2001 (BW HealthWire) -- Charles River Laboratories International, Inc. (NYSE:CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., today announced that it has entered into a definitive agreement to acquire Genetic Models, Inc. (GMi).
WILMINGTON, Mass.--(BW HealthWire)--June 22, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to file a registration statement with the Securities and Exchange Commission on June 25, 2001 for a proposed underwritten offering of 8,000,000 shares of its
WILMINGTON, Mass.--(BW HealthWire)--June 14, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is raising its previous guidance on estimated earnings per share performance for the second quarter. The Company estimates second quarter earnings per fully-diluted
WILMINGTON, Mass.--(BW HealthWire)--May 3, 2001--Charles River Laboratories International, Inc. (NYSE: CRL), reported today that sales increased 37% in the first quarter of 2001 over the prior year. Sales for the first quarter were $99.0 million, a $26.5 million increase over first quarter 2000
WILMINGTON, Mass.--(BW HealthWire)--April 27, 2001--Charles River Laboratories International, Inc. (NYSE:CRL) and Charles River Laboratories, Inc. (together "Charles River") have scheduled a conference call to discuss first quarter 2001 financial results.
WILMINGTON, Mass.--(BW HealthWire)--March 21, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it closed its public offering of 8,050,000 shares of common stock (which included the underwriters' over-allotment option to purchase an additional 1,050,000 shares)
WILMINGTON, Mass.--(BW HealthWire)--March 16, 2001--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it had priced its public offering of 7,000,000 shares of common stock (excluding the underwriters' over-allotment option to purchase an additional 1,050,000 shares of
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 27, 2001--Charles River Laboratories International, Inc. (NYSE:CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., today announced the completion of the acquisition of Primedica Corporation from Genzyme Transgenics Corporation
WILMINGTON, Mass.--(BW HealthWire)--Feb. 15, 2001--Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed public offering of 7,000,000 shares of its common stock.
BOSTON--(BW HealthWire)--Feb. 14, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will file a registration statement with the Securities and Exchange Commission on February 15, 2001 for a proposed underwritten offering of 7,000,000 shares of its common
WILMINGTON, Mass.--(BW HealthWire)--Feb. 14, 2001--Charles River Laboratories International, Inc. (NYSE:CRL -news) and its wholly-owned subsidiary, Charles River Laboratories, Inc., reported today that sales increased 33% in the fourth quarter of 2000 over the prior year, driven by strong growth in
WILMINGTON, Mass.--(BW HealthWire)--Feb. 9, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) and Charles River Laboratories, Inc. (together "Charles River") have scheduled a conference call to discuss fourth quarter 2000 financial results.
WILMINGTON, Mass.--(BW HealthWire)--Feb. 7, 2001--Charles River Laboratories International, Inc. (NYSE:CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., today announced the signing of a a definitive agreement to acquire Primedica Corporation from Genzyme Transgenics
WILMINGTON, Mass.--(BW HealthWire)--Jan. 30, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) and its wholly-owned operating subsidiary, Charles River Laboratories, Inc., have each had their credit ratings raised by Moody's and Standard & Poor's.
Wilmington, MA.; January 8, 2001: Charles River Laboratories International, Inc. (NYSE:CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., today announced the completion of the acquisition of Pathology Associates International Corporation (PAI).
WILMINGTON, Mass.--(BW HealthWire)--Dec. 21, 2000--Charles River Laboratories International, Inc. (NYSE:CRL), through its wholly-owned subsidiary Charles River Laboratories, Inc., today announced the signing of a definitive agreement to acquire Pathology Associates International Corporation from
WILMINGTON, Mass.--(BW HealthWire)--Dec. 11, 2000--Responding to inquiries from the New York Stock Exchange, management at Charles River Laboratories International, Inc. (NYSE:CRL) advises that it is not aware of any adverse events or coverage that might explain the substantial decline in the stock
WILMINGTON, Mass.--(BW HealthWire)--Dec. 4, 2000--Charles River Laboratories, Inc. (NYSE: CRL) has entered into an agreement with the Tufts University School of Veterinary Medicine to further develop and commercialize a novel cloning technology, applied to immunodeficient mice.
WILMINGTON, Mass.; November 27, 2000: The fourth quarter sales and earnings outlook for Charles River Laboratories International, Inc. (NYSE: CRL) is expected to exceed the current analysts’ estimates. The Company estimates fourth quarter 2000 sales to be $72 million to $74 million versus the
WILMINGTON, Mass.--(BW HealthWire)--Nov. 1, 2000--Charles River Laboratories International, Inc.'s (NYSE:CRL) sales increased 37% in the third quarter over the prior year, driven by strong growth in customer demand for its drug discovery and development products and services.
WILMINGTON, Mass.--(BW HealthWire)--Oct. 23, 2000--Charles River Laboratories International, Inc. (NYSE:CRL) and Charles River Laboratories, Inc. (together "Charles River") have scheduled a conference call to discuss third quarter 2000 financial results.
WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 2, 2000--Charles River Laboratories International, Inc. (NYSE: CRL) reported today that second quarter 2000 sales increased by 32.6%, to $74.1 million from $55.9 million, over the second quarter of 1999, while net income was $8.0 million or $0.34 per diluted
WILMINGTON, Mass.--(BUSINESS WIRE)--July 10, 2000--Charles River Laboratories, Inc. announced today that it will redeem 35% of the aggregate principal amount of its 13 1/2% Senior Subordinated Notes due 2009, pursuant to the "IPO clawback" provisions of the Notes.
WILMINGTON, Mass., June 26 /PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE: CRL) announced its initial public offering of 14,000,000 shares of its common stock on Friday, June 23 at an initial public offering price of $16.00 per share.
Charles River Laboratories, Inc. , a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development, today reported its first quarter results. For the first quarter ended March 25, 2000, Charles River's net sales were
Charles River Laboratories Holdings, Inc.,a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development, announced today that it has filed a registration statement with the Securities and Exchange Commission for a
Charles River Laboratories Holdings, Inc. , a provider of products and services used primarily in pre-clinical drug discovery and development, today reported its fourth quarter and year-end financial results. For the fourth quarter ended December 25, 1999, Charles Rivers net sales were $58.2
